Galecto to Participate at H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

Galecto, Inc. (NASDAQ: GLTO), a biotechnology firm, announced participation in H.C. Wainwright’s 24th Annual Global Investment Conference from September 12-14, 2022. Management will engage in virtual 1x1 meetings with investors, and a webcast of the presentation will be available for replay on Galecto’s website. The company focuses on developing inhibitors for fibrosis and cancer, with four ongoing Phase 2 clinical trials targeting conditions like idiopathic pulmonary fibrosis and non-small cell lung cancer.

BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that management will be participating at the upcoming H.C. Wainwright’s 24^th Annual Global Investment Conference taking place on September 12-14, 2022. Details for the event are as follows:

H.C. Wainwright 24th Annual Global Investment Conference
Date:		September 12-14, 2022
Webcast:		Click HERE

Management will be available for virtual 1x1 meetings with investors. Please contact your H.C. Wainwright representative to request a meeting.

A replay of the webcast presentation will be available in the Investor section of Galecto’s website at https://ir.galecto.com/news-and-events/events.

About Galecto
Galecto is a clinical stage company incorporated in the U.S. that is developing small molecule-based inhibitors of galectin-3 and LOXL2. Galecto has four ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a phase 2b trial for the treatment of idiopathic pulmonary fibrosis (IPF); (ii) an orally active LOXL2 inhibitor (GB2064) in a phase 2 trial for the treatment of myelofibrosis; (iii) an orally active galectin-3 inhibitor (GB1211) in a phase 1b/2a trial in liver cirrhosis and (iv) an orally active galectin-3 inhibitor (GB1211) in a separate phase 2 trial for the treatment of non-small cell lung cancer (NSCLC) in combination with atezolizumab (Tecentriq®).

Galecto intends to use its website as a means of disclosing material non-public information. For regular updates about Galecto, visit www.galecto.com.

For more information, contact:

Galecto, Inc.
Hans Schambye, CEO
Jon Freve, CFO
+45 70 70 52 10
Investors/US	Media/EU
Ashley R. Robinson	Sandya von der Weid
arr@lifesciadvisors.com	svonderweid@lifesciadvisors.com
+1 617 430 7577	+41 78 680 0538

FAQ

When is Galecto participating in the H.C. Wainwright 24th Annual Global Investment Conference?

Galecto is participating in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022.

How can I access the webcast for Galecto's presentation at the conference?

The webcast for Galecto's presentation can be accessed via their website or directly through the event link provided in the press release.

What are the key clinical programs Galecto is currently working on?

Galecto is developing inhibitors for conditions like idiopathic pulmonary fibrosis, myelofibrosis, liver cirrhosis, and non-small cell lung cancer.

Where can I find more information about Galecto's clinical trials?

More information about Galecto's clinical trials can be found on their official website in the Investor section.

Who should I contact for investor inquiries regarding Galecto?

For investor inquiries, you can contact Ashley R. Robinson via email at arr@lifesciadvisors.com or call +1 617 430 7577.